Do patients with submassive pulmonary embolism benefit from thrombolytic therapy?

Ali Ataya; Jessica Cope; Abbas Shahmohammadi; Hassan Alnuaimat

doi:10.3949/ccjm.83a.15116

Do patients with submassive pulmonary embolism benefit from thrombolytic therapy?

Cleve Clin J Med. 2016 Dec;83(12):923-932. doi: 10.3949/ccjm.83a.15116.

Authors

Ali Ataya¹, Jessica Cope², Abbas Shahmohammadi³, Hassan Alnuaimat⁴

Affiliations

¹ Pulmonary Hypertension Program, Division of Pulmonary, Critical Care, and Sleep Medicine, University of Florida, Gainesville, FL, USA. E-mail: aliataya@gmail.com.
² Pulmonary Hypertension Program, Department of Pharmacy, University of Florida, Gainesville, FL, USA.
³ Division of Pulmonary, Critical Care, and Sleep Medicine, University of Florida, Gainesville, FL, USA.
⁴ Pulmonary Hypertension Program, Division of Pulmonary, Critical Care, and Sleep Medicine, University of Florida, Gainesville, FL, USA.

PMID: 27938515
DOI: 10.3949/ccjm.83a.15116

Abstract

Despite growing interest in thrombolytic agents to treat submassive pulmonary embolism, their role in this scenario remains controversial. Needed is a way to identify patients with this condition who are at risk of clinical deterioration and who would benefit from thrombolytic therapy. Here, we review the use of thrombolytic agents in submassive pulmonary embolism to help distinguish the risk and benefits of this therapy.

Publication types

Review

MeSH terms

Humans
Pulmonary Embolism / diagnosis
Pulmonary Embolism / drug therapy*
Thrombolytic Therapy*